{"title":"Induction of c-fos protooncogene transcription and apoptosis by Δ12-prostaglandin J2 in human Pl-21 myeloid leukemia and RC-K8 pre-B lymphoma cells","authors":"Ko-ichi Higashiyama , Kenji Niiya , Tetsuo Ozawa , Yumiko Hayakawa , Masao Fujimaki , Nobuo Sakuragawa","doi":"10.1016/S0090-6980(96)00093-7","DOIUrl":null,"url":null,"abstract":"<div><p><em>Δ</em><sup>12</sup>-prostaglandin J<sub>2</sub> (PGJ<sub>2</sub>) is a dehydration product of PGD<sub>2</sub> and thought to be the most potent antitumor agent among prostaglandin compounds. We examine the cytotoxic effects of PGJ<sub>2</sub> on the cell growth of leukemia/lymphoma cells. PGJ<sub>2</sub> inhibited the growth of both human PL-21 myeloid leukemia and RC-K8 pre-B lymphoma cells in culture in a dose-dependent manner with fragmentation of nucleus and formation of apoptotic body. Agarose gel electrophoresis revealed DNA ladder formation in the cells treated with PGD<sub>2</sub>. Furthermore, PGJ<sub>2</sub> induced a rapid and transient expression of apoptosis-related protooncogene, <em>c-fos</em>, in both cells. The gene transcriptional rate was remarkably increased approximately 3.3-fold in PGJ<sub>2</sub> treated cells, but the stability of <em>c-fos</em> mRNA was not significantly changed. Inhibition of <em>de novo</em> protein synthesis with cycloheximide increased <em>c-fos</em> mRNA stability but not abrogated PGJ<sub>2</sub>-induced c-fos transcription. These data suggest that PGJ<sub>2</sub> can induce apoptosis of human leukemia/lymphoma cells and the rapid activation of c-fos protooncogene transcription in which <em>de novo</em> protein synthesis is not required.</p></div>","PeriodicalId":20653,"journal":{"name":"Prostaglandins","volume":"52 3","pages":"Pages 143-156"},"PeriodicalIF":0.0000,"publicationDate":"1996-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0090-6980(96)00093-7","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090698096000937","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22
Abstract
Δ12-prostaglandin J2 (PGJ2) is a dehydration product of PGD2 and thought to be the most potent antitumor agent among prostaglandin compounds. We examine the cytotoxic effects of PGJ2 on the cell growth of leukemia/lymphoma cells. PGJ2 inhibited the growth of both human PL-21 myeloid leukemia and RC-K8 pre-B lymphoma cells in culture in a dose-dependent manner with fragmentation of nucleus and formation of apoptotic body. Agarose gel electrophoresis revealed DNA ladder formation in the cells treated with PGD2. Furthermore, PGJ2 induced a rapid and transient expression of apoptosis-related protooncogene, c-fos, in both cells. The gene transcriptional rate was remarkably increased approximately 3.3-fold in PGJ2 treated cells, but the stability of c-fos mRNA was not significantly changed. Inhibition of de novo protein synthesis with cycloheximide increased c-fos mRNA stability but not abrogated PGJ2-induced c-fos transcription. These data suggest that PGJ2 can induce apoptosis of human leukemia/lymphoma cells and the rapid activation of c-fos protooncogene transcription in which de novo protein synthesis is not required.